Centro de Estudios de Estado y Sociedad/Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.
Centro de Estudios de Estado y Sociedad, Buenos Aires, Argentina.
BMC Cancer. 2024 Aug 12;24(1):996. doi: 10.1186/s12885-024-12650-7.
The 2021 World Health Organization (WHO) guidelines on cervical cancer screening and treatment provide countries with evidence-based recommendations to accelerate disease elimination. However, evidence shows that health providers' adherence to screening guidelines is low. We conducted a study in Argentina to analyze health providers' knowledge and perceptions regarding the 2021 WHO Guidelines.
A qualitative study was conducted based on individual, semi-structured interviews with health providers specializing in gynecology (n = 15). The themes explored were selected and analyzed using domains and constructs of the Consolidated Framework for Implementation Research.
Although health providers perceive WHO as a reliable institution, they do not know the 2021 guidelines, its supporting evidence, and its elaboration process. Their clinical practice is mainly guided by local recommendations developed by national professional medical associations (PMAs). For interviewees, WHO guidelines should be disseminated through health authorities and national PMAs, mainly through in-service training. Health providers had a positive assessment regarding WHO Recommendation 1 (screen, triage, and treatment for women aged 30 + with HPV-testing every 5 to 10 years) and perceived a favorable climate for its implementation. HPV-testing followed by triage was considered a low-complexity practice, enabling a better detection of HPV, a better selection of the patients who will need diagnosis and treatment, and a more efficient use of health system resources. However, they suggested adapting this recommendation by removing screening interval beyond 5 years. WHO Recommendation 2 (screen-and-treat approach with HPV-testing for women aged 30 + every 5 to 10 years) was predominantly rejected by interviewees, was considered an algorithm that did not respond to women's needs, and was not adequate for the Argentinean context. Regarding the HPV-test modality, clinician-collected tests were the preferred mode. Health providers considered that HPV self-collection should be used primarily among socially vulnerable women to increase screening coverage.
WHO guidelines should be widely disseminated among health providers, especially in settings that could benefit from a screen-and-treat approach. Identifying areas of partnership and collaboration with PMAs in implementing WHO guidelines is essential.
2021 年世界卫生组织(WHO)宫颈癌筛查和治疗指南为各国提供了加速消除疾病的循证建议。然而,有证据表明卫生保健提供者对筛查指南的遵循率较低。我们在阿根廷开展了一项研究,以分析卫生保健提供者对 2021 年 WHO 指南的知识和看法。
基于对专门从事妇科的卫生保健提供者(n=15)的个人、半结构化访谈,开展了一项定性研究。使用实施研究综合框架的领域和结构来选择和分析探索的主题。
尽管卫生保健提供者认为世卫组织是一个可靠的机构,但他们并不了解 2021 年指南、其支持证据及其制定过程。他们的临床实践主要由国家专业医学协会(PMA)制定的地方建议指导。对于受访者来说,世卫组织指南应该通过卫生当局和国家 PMA 传播,主要通过在职培训进行。卫生保健提供者对世卫组织建议 1(对 30 岁以上 HPV 检测每 5-10 年的女性进行筛查、分类和治疗)进行了积极评估,并认为实施该建议的氛围良好。HPV 检测加分类被认为是一种低复杂性的做法,可以更好地检测 HPV,更好地选择需要诊断和治疗的患者,并更有效地利用卫生系统资源。然而,他们建议通过将筛查间隔延长至 5 年以上来调整该建议。受访者主要拒绝了世卫组织建议 2(对 30 岁以上 HPV 检测每 5-10 年的女性进行筛查和治疗),认为这是一种不能满足女性需求的算法,并且不适合阿根廷的情况。关于 HPV 检测方式,临床医生采集的样本是首选模式。卫生保健提供者认为,HPV 自我采集应该主要用于社会弱势群体,以提高筛查覆盖率。
应在世卫组织指南广泛传播,特别是在可以从筛查和治疗方法中受益的环境中。在世卫组织指南的实施中,与 PMA 确定合作领域和伙伴关系至关重要。